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THE MECHANISM OF ACTION OF THE C3b INACTIVATOR
(CONGLUTINOGEN-ACTIVATING FACTOR) ON ITS
NATURALLY OCCURRING SUBSTRATE,THEMAJORFRAGMENT
OF THE THIRD COMPONENT OF COMPLEMENT (C3b)*
By JONATHAN D . GITLIN, FRED S. ROSEN,t AND PETER J . LACHMANN
(From the Medical Research Council Research Group on Serum Complement, Department of
Immunology, Royal Postgraduate Medical School, London W12, England)
The fixation of the third component of complement (C3) results in many important biological
phenomena, amongwhich are (a) immune adherence (1), (b) enhancement of phagocytosis (2, 3), (c)
the release of an anaphylatoxin which is a potent releaser of histamine (4), and (d) the feedback
activation of the alternative pathway (5, 6) . The physiological mechanisms involving C3 fixation
require the generation of a C3 convertase which may occur by two separate pathways . C3 convertase
can be generated, in the form of C42, by the so-called classical pathway of activation or in the form
C3b,B by the alternative or properdin pathway (7) . In both cases, C3 is converted to C3bby cleavage
of a small peptide, C3a. Normalhuman serum contains an inactivator of activated C3b . This C3b in-
activator or conglutinogen-activating factor (KAF) hasbeen shown to inhibit both immune hemolysis
and the immune adherence properties of C3b and to cause cleavage of C3b in the fixed and fluid-
phase .stages (8-11) .
Although it is known that the Cabinactivator is not depleted during its reaction withCab
and that C3b treated with the Cab inactivator becomes extremely sensitive to proteolytic
digestion by trypsin and "trypsin-like" enzymes (9), the exact molecular nature of the
action of the C3b inactivator on C3b has not been studied . In an effort to delineate the
products of this interaction, purified Cab and Cab inactivator were allowed to react for
various specific lengths of time and the products of these reactions were then analyzed .
Materials and Methods
Purified Serum Proteins. C3 was purified by a modification of the method of Nilsson and
Miiller-Eberhard (12) and subsequently labeledwith"I by the iodine monochloride technique (13) .
C3b inactivator was also purified from normal human serum (14) . 20 mg of cobravenom factor (CVF)
was isolated from Naja naja venom (Sigma Chemical Co ., St . Louis, Mo .) by DEAE-cellulose
chromatography and gel filtration on Sephadex G-200 (15) and subsequently conjugated to 2 ml of
packed cyanogen bromide-treated 413 Sepharose beads (Pharmacia Fine Chemicals, Inc ., Uppsala,
Sweden) . 0 .1 ml of CVF-Sepharose was reacted with 0.4 ml offresh normal humanserum at 37*C for
15 min in order to generate C3 convertase . The CVF-Sepharose beads were then centrifuged and
washed with chilled phosphate-buffered saline . C3bwas generatedby incubation of purified C3 with
serum-exposed, washed CVF-Sepharose beads for 45 min at 37*C which results in the loss of
hemolytic C3 activity (L . Halbachs and P. J . Lachmann, unpublished observations) .
Fresh human serum was saturated to 20% with sodium sulphate . The precipitate was discarded,
and the supernate was chromatographed on 0-(carboxymethyl)cellulose as previously described to
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isolate a fraction containing partially purified factor B and factor D (16) .
Enzymes andInhibitors.
￿
Trypsin (Sigma Chemical Co.) wasstored in HCl under liquid N, before
use. Diisopropylfluorophosphate (DFP) was purchased from Sigma Chemical Co. and used at a final
concentration of 10-3 M. Antrypol was obtained as Suramin-BP from FBA Pharmaceuticals, Inc.,
New York, and wasused to render C3bresistant to KAF at a concentration of 1 mg/ml (14).
Reactions .
￿
All reactions were carried out at 37°C in 10-ml plastic tubes placed in a rotary-stir
water bath . Time-course reactions were stopped at the designated time by addition of antrypol to the
reaction vessel and removal of the tube from the 37°C bath. All necessary dilutions were made with
0.01 M sodium phosphate buffer at pH 7.
Polyacrylamide Gel Electrophoresis. Reaction products were analyzed by polyacrylamide gel
electrophoresis in sodium dodecyl sulphate (SDS) according to the methods of Weber and Osborn
(17). The reaction mixture was at first dialyzed for 6 h against 0.1 M sodium phosphate buffer pH 7
andthen prepared in 0.01 M sodium phosphate pH 7containing 1% SDS and 1% 2-mercaptoethanol
and applied to the polyacrylamide gels. After destaining, gels were cut into 2-mm slices, placed in
1mM proprionic acid, and analyzed for radioactivity.
Functional Assay of C3b.
￿
The capacity of C3b before andafter treatment with the C3 inactivator
to activate the alternative pathway wasassayed by the inactivation of the hemolytic activity of factor
B by C3b in the presence of factor D. The hemolytic activity of factor B was measured by thesingle
radial diffusion assay of Martin and Lachmann (18), which is based on thebystander lysis of guinea
pig erthrocytes when the alternative pathwayof human C is activated. Agarose plates incorporating
0.5% guinea pig erythrocytes, 5% human serum heated for 20 min at 50°C, 10 mM EDTA, and 7 mM
Mg++ are used for the assay.
Results
Purified human C3 consists of a single heavy or alpha chain and a single light or
beta chain joined by interchain disulphide bonds which can be resolved by
polyacrylamide gel electrophoresis in SDS and separated by reduction and
alkylation followed by gel filtration chromatography. Purified human Cab, when
generated from C3 by CVF-Sepharose convertase, yields three protein bands
when resolved by electrophoresis in SDS-polyacrylamide gels as indicated inFig.
1. The band with a mol wt of 180,500 represents intact C3b, the 110,000 mol wt
band represents the alpha chain, and the beta chain moiety ofC3b is resolved as
a band of mol wt 70,000. Fig. 1 illustrates that after incubation of Cab with
purified C3 inactivator for 3 min, the 110,000 band representing the alpha or
heavy chain disappears and a new protein fragment of 85,000 mol wt can be
discerned. Furthermore, it is apparent from Fig. 1 that the protein band
representing the light or beta chain of Cab is unchanged after 3 min incubation
with C3 inactivator.
Further incubation of C3b with C3 inactivator results in gradual degredation of the 87,000 dalton
fragment. As Fig. 1 indicates, after 3 h of incubation, almost complete disappearance of both the
110,000 fragment of C3b andthe85,000 fragment generated after 3 minutes of C3binactivator action
on the C3b substrate occurs. In fact, almost all of the protein appears in the 70,000 mol wt band after
3 h incubation . The reactions illustrated in Fig. 1 cannot be inhibited by DFPup to aconcentration of
10-3 M.
Since it is known that the action of CA inactivatoron its cell-bound substrate,
C3b renders C3b exquisitely sensitive to proteolytic digestion by trypsin (9),
further incubations were carried out in the presence ofvarious concentrations of
trypsin. Fig. 2 illustrates that incubation of C3b with trypsin had no effect upon
the size ofthe alpha or beta chains of the C3b as resolved in SDS-polyacrylamide
gels.GITLIN ET AL .
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FIG . 1 . Polyacrylamide gel electrophoresis in SDS of C3b ("-"), C3b reacted with C3
inactivator for 3 min (0 . . . . 0), and C3b reacted with C3 inactivator for 3 h (0---0) .
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Polyacrylamide gel electrophoresis in SDS of C3b treated with trypsin for 75 min at
37°C ("-")or C3b treated with trypsin after prior reaction with C3 inactivator for 3 min
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No effect was seen with trypsin concentrations from 0.1 to 10 Pg/ml, a concentration of trypsin 100-
fold in exesss to that needed to proteolyse C3 inactivator-treated, cell-bound Cab. The results of
treatment of Cab preincubated with the Cab inactivator for 3 min with concentrations of trypsin
down to 0.1 Aag/ml are also shown in Fig. 2. From this it is clear that only the protein bands at the
70,000 mol wt range appear after such trypsin treatment of Cab which has been preincubated for 3
min with the Cab inactivator. Indeed, the results of such treatment are remarkably similar to those
seen after incubation of C3b with its inactivator for 3 h.
When 8.6 kg of C3b were interacted with 560lAg of factor B at 37°C for 30 min, the factor Blost its
hemolytic capacity as measured by bystander lysis of guinea pig erythrocytes. On the other hand, it
required 86 jug of C3 treated for 3 minwith C3 inactivator at 37°C to bring about acomparable loss of
hemolytic activity of 560ug of factor B. Thus, C3btreated with C3 inactivator for 3 minlost over 90%
of its capacity to inactivate factor B in the presence of factor D.
Discussion
From the results presented here, it is apparent that the C3b inactivator
proteolytically cleaves C3b. Furthermore, the reaction of the C3b inactivator is
twofold in nature; the first cleavage, which is initiated rapidly, is essentially
completed in 3 min. The second reaction, which is much slower, requires 3 h to
reach completion . Since electrophoresis of the reaction products in SDS-polya-
crylamide gel allows resolution of the heavy and light chains, it is clearthat both
enzymatic cleavages by the C3b inactivator occur at sites on the heavy chains of
the intact molecule . The first reaction product, composed of alpha 85,000, beta
70,000, should properly be designated C3b', as this reaction product is inactive
with regard to the capacity of C3b to activate the alternative pathway. The
product of the second reaction, composed of alpha 70,000, beta 70,000, resembles
C3c purified from aged serum. The conditions under which the gels were run re-
sulted in failure to detect the smaller cleavage.fragments.
The data also clearly indicate that the second slow reaction of the C3b
inactivator can also be accomplished by very small concentrations of trypsin
upon completion of the first, fast reaction . However, no effect on C3b is seen by
trypsin in concentrations 100-fold in excess of this when the first, fast reaction of
the C3b inactivator has not occurred . Thus, C3b is relatively trypsin resistant
compared with the exquisite sensitivity of C3b' to tryptic cleavage. It is important
to note that since such minute concentrations of trypsin are required to mimic
the second, slow reaction of the C3b inactivator, the possibility of its contamina-
tion by another trypsin-like protease is very real. Leukocytes and platelets are
known to contain significant amounts of trypsin-like proteases, and the possibil-
ity of contamination on the scale needed cannot be excluded by the methods
employed.
A patient with a genetically determined deficiency of the Cab inactivator has
been studied in great detail (19, 20) . His serum contains small amounts of C3b so
that the alternative pathway in his blood is constantly subject to feedback
activation. The intravenous administration of purified C3b inactivator causes a
prompt conversion of his C3b to C3c and a cessation of in vivo activation of the
alternative pathway in the patient's plasma (21) . It appears likely that in the
conversion of C3b to C3b' the capacity of C3bto activate the alternative pathway
has been destroyed whilethe conglutinable and opsonically active fragment of C3
has been formed, facilitating phagocytic uptake of particles coated with this
moiety of C3 (22) .GITLIN ET AL .
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